{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T04:24:20Z","timestamp":1771302260711,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.eprac.2024.12.005","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T18:05:10Z","timestamp":1733940310000},"page":"315-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Once-Weekly Tirzepatide Versus Once-Daily Basal Insulin in Managing Type 2 Diabetes Inadequately Controlled With Oral anti-Hyperglycemic Drugs: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5681-6522","authenticated-orcid":false,"given":"A.B.M.","family":"Kamrul-Hasan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahjada","family":"Selim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faria","family":"Afsana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmi","family":"Nagendra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rezwana","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deep","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.eprac.2024.12.005_bib1","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"On behalf of the American diabetes association. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.005_bib2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/ph12040152","article-title":"Sugar-lowering drugs for type 2 diabetes mellitus and metabolic syndrome-review of classical and new compounds: Part-I","volume":"12","author":"Vieira","year":"2019","journal-title":"Pharmaceuticals"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.eprac.2024.12.005_bib3","first-page":"S41","article-title":"Approaches to glycemic treatment. Sec. 7. In standards of medical care in diabetes\u20132015","volume":"38","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2024.12.005_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.838410","article-title":"Recent advances in incretin-based pharmacotherapies for the treatment of obesity and diabetes","volume":"13","author":"Tan","year":"2022","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.005_bib5","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s13300-018-0395-3","article-title":"Basal insulin intensification in patients with type 2 diabetes: a review","volume":"9","author":"Meece","year":"2018","journal-title":"Diabetes Ther"},{"issue":"7","key":"10.1016\/j.eprac.2024.12.005_bib6","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"Wing","year":"2011","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.005_bib7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"10300","key":"10.1016\/j.eprac.2024.12.005_bib8","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.005_bib9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S2213-8587(22)00077-8","volume":"10","author":"Battelino","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.005_bib10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10313","key":"10.1016\/j.eprac.2024.12.005_bib11","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.eprac.2024.12.005_bib12","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.005_bib13","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41591-023-02344-1","article-title":"Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial","volume":"29","author":"Gao","year":"2023","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.eprac.2024.12.005_bib14","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis","volume":"65","author":"Karagiannis","year":"2022","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.eprac.2024.12.005_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102640","article-title":"Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials","volume":"16","author":"Permana","year":"2022","journal-title":"Diabetes Metabol Syndr"},{"issue":"15","key":"10.1016\/j.eprac.2024.12.005_bib16","first-page":"7164","article-title":"Is tirzepatide 15 mg the preferred treatment strategy for type 2 diabetes? A meta-analysis and trial-sequence-analysis","volume":"27","author":"Yang","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"10.1016\/j.eprac.2024.12.005_bib17","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/dom.14988","volume":"25","author":"Nauck","year":"2023","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.eprac.2024.12.005_bib18","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.005_bib19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3803\/EnM.2023.1839","article-title":"Efficacy and safety of omarigliptin, a novel once-weekly dipeptidyl peptidase-4 inhibitor, in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"39","author":"Kamrul-Hasan","year":"2024","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.eprac.2024.12.005_bib20","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.005_bib21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"10","key":"10.1016\/j.eprac.2024.12.005_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4100","article-title":"Publication and related biases","volume":"4","author":"Song","year":"2000","journal-title":"Health Technol Assess"},{"issue":"5","key":"10.1016\/j.eprac.2024.12.005_bib23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.005_bib24","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"SURPASS-2 investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.005_bib25","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/00325481.2022.2051366","article-title":"What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review","volume":"134","author":"Horn","year":"2022","journal-title":"Postgrad Med"},{"key":"10.1016\/j.eprac.2024.12.005_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics","volume":"267","author":"Nicholls","year":"2024","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.005_bib27","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s13300-019-0627-1","article-title":"Pancreatitis incidence in the exenatide BID, exenatide QW, and exenatide QW suspension development programs: pooled analysis of 35 clinical trials","volume":"10","author":"Vetter","year":"2019","journal-title":"Diabetes Ther"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.005_bib28","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/dom.12885","article-title":"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes","volume":"19","author":"Storgaard","year":"2017","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.eprac.2024.12.005_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111806","article-title":"The incidence of acute pancreatitis with GLP-1 receptor agonist therapy in individuals with a known history of pancreatitis","volume":"215","author":"Lomeli","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"10.1016\/j.eprac.2024.12.005_bib30","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern Med"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24008619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24008619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T18:50:09Z","timestamp":1741027809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X24008619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1530891X24008619"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.12.005","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Once-Weekly Tirzepatide Versus Once-Daily Basal Insulin in Managing Type 2 Diabetes Inadequately Controlled With Oral anti-Hyperglycemic Drugs: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}